Zostavax Europska Unija - hrvatski - EMA (European Medicines Agency)

zostavax

merck sharp & dohme b.v. - virus varicella-zoster (živ, atenuiran) - herpes zoster; immunization - virusna cjepiva - zostavax je indiciran za prevenciju herpes zoster ("zoster" ili šindre) i post-herpetičke neuralgije povezane s herpes zosterom. zostavax prikazana je za cijepljenje osoba u dobi od 50 i više godina.

Fulvestrant Mylan Europska Unija - hrvatski - EMA (European Medicines Agency)

fulvestrant mylan

mylan pharmaceuticals limited - fulvestrant od - neoplazme dojki - endokrinska terapija - fulvestrant indiciran za liječenje estrogen receptor pozitivni, lokalno-održao ili метастатического raka dojke kod žena u postmenopauzi:ne ranije liječenih endokrine terapije, orwith recidiva bolesti nakon adjuvantne terapije anti -- estrogena, ili progresiju bolesti na terapiju антиэстрогенами.

Faslodex Europska Unija - hrvatski - EMA (European Medicines Agency)

faslodex

astrazeneca ab - fulvestrant od - neoplazme dojki - endokrini terapija, anti-estrogeni - faslodex is indicated , as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:, , not previously treated with endocrine therapy, or, with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy. , , , in combination with palbociclib for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy. u pre - ili perimenopauzi, u sveobuhvatnoj liječenju s palbociclib treba kombinirati s luteinizirajućeg hormona releasing hormon (lhrh) agonist.